Form 4: Axsome Therapeutics General Counsel Completes Pre-Scheduled Share Sales Under 10b5-1 Plan

Axsome Therapeutics' General Counsel, Hunter R. Murdock, completed pre-scheduled transactions under a 10b5-1 plan, exercising stock options and immediately selling the acquired common stock for total proceeds exceeding $1.37 million.

Summary

• Hunter R. Murdock, General Counsel of Axsome Therapeutics, Inc. (AXSM), executed two sets of transactions involving company common stock as part of a pre-approved Rule 10b5-1 trading plan, which has now been completed.
• On June 20, 2025, Mr. Murdock exercised options to acquire 7,500 shares of common stock at an exercise price of $29.91 per share.
• Immediately following the exercise on June 20, 2025, he sold all 7,500 shares at a weighted average price of $102.47 per share, generating approximately $768,525 in proceeds.
• On June 23, 2025, Mr. Murdock exercised options to acquire an additional 6,014 shares of common stock at an exercise price of $29.91 per share.
• Concurrently on June 23, 2025, he sold all 6,014 shares at a weighted average price of $100.12 per share, generating approximately $602,120.68 in proceeds.
• Following these transactions, Mr. Murdock's direct beneficial ownership of common stock is 0 shares, while he retains 16,369 stock options.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction (exercise and sell) under a 10b5-1 plan, which is a common practice for executives to manage their equity compensation. It does not inherently signal positive or negative company performance or strategic shifts.

Positives

• The transactions were executed under a pre-approved 10b5-1 plan, indicating a pre-scheduled event rather than a reaction to specific market news, which often reduces concerns about opportunistic insider selling.
• The sale prices ($102.47 and $100.12 per share) are significantly higher than the exercise price ($29.91 per share), indicating a substantial gain for the insider on these specific option exercises.

Negatives

• An insider selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces their direct equity stake.
• The General Counsel's direct beneficial ownership of common stock is now 0 shares, although he retains a significant number of stock options.

Future Outlook

This Form 4 filing reports past transactions and does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• "Such transaction was pursuant to a pre-approved 10b5-1 plan which has now been completed."

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends for the pharmaceutical or biotechnology sector. It reflects an individual's equity compensation management rather than a strategic corporate move.

Comparison to Industry Standards

• As a routine insider transaction report (Form 4), this document does not contain information suitable for direct comparison to industry-specific financial benchmarks or competitor performance.
• The transactions reflect the individual's exercise of vested stock options and subsequent sale, which is a common practice for executives managing their personal equity holdings and is consistent with standard equity compensation practices across industries.

Stakeholder Impact

• Shareholders: The sale of shares by an insider, even under a 10b5-1 plan, slightly increases the public float. While generally routine for compensation management, some investors might interpret any insider selling as a minor negative signal, though this is typically mitigated by the pre-planned nature of 10b5-1 transactions.
• Employees, Customers, Suppliers, Creditors: No direct or material impact on these stakeholders is indicated by this filing.

Next Steps

• No specific future actions or milestones for the company are mentioned in this insider transaction report. The 10b5-1 plan under which these transactions occurred has been completed.

Key Dates

Keywords

Axsome Therapeutics, AXSM, Form 4, Insider Trading, Stock Options, 10b5-1 Plan, Hunter R. Murdock, General Counsel, Share Sale, Equity Compensation